Clinicopathological characteristics and outcomes of ROS1‐rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements

By  

Thoracic Cancer, Vol. 6, Iss. 4, 2015-07 ,pp. : 413-420

John Wiley & Sons Inc

Access to resources Recommend Favorite

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review

By  

Thoracic Cancer, Vol. 9, Iss. 1, 2018-01 ,pp. : 159-163

John Wiley & Sons Inc

Access to resources Recommend Favorite

Subsequent treatment of epidermal growth factor receptor‐tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 678-686

John Wiley & Sons Inc

Access to resources Recommend Favorite

Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China

By  

Thoracic Cancer, Vol. 6, Iss. 5, 2015-09 ,pp. : 636-642

John Wiley & Sons Inc

Access to resources Recommend Favorite

TGF‐β regulates the proliferation of lung adenocarcinoma cells by inhibiting PIK3R3 expression

By  

Molecular Carcinogenesis, Vol. 54, Iss. S1, 2015-06 ,pp. : E162-E171

John Wiley & Sons Inc

Access to resources Recommend Favorite